Search

Ta Hsung Tung

Examiner (ID: 4022)

Most Active Art Unit
1102
Art Unit(s)
1744, 1104, 1753, 1106, 1102, 1743, 2899, 2701, 2901
Total Applications
1660
Issued Applications
1317
Pending Applications
54
Abandoned Applications
289

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 16343632 [patent_doc_number] => 20200308282 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING [patent_app_type] => utility [patent_app_number] => 16/827580 [patent_app_country] => US [patent_app_date] => 2020-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39734 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16827580 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/827580
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING Mar 22, 2020 Abandoned
Array ( [id] => 16613664 [patent_doc_number] => 20210032317 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => VISTA-IG FOR TREATMENT OF AUTOIMMUNE, ALLERGIC AND INFLAMMATORY DISORDERS [patent_app_type] => utility [patent_app_number] => 16/820116 [patent_app_country] => US [patent_app_date] => 2020-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 89947 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16820116 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/820116
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders Mar 15, 2020 Issued
Array ( [id] => 16525286 [patent_doc_number] => 20200399366 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-24 [patent_title] => METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/818820 [patent_app_country] => US [patent_app_date] => 2020-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54829 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16818820 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/818820
METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS Mar 12, 2020 Abandoned
Array ( [id] => 16283778 [patent_doc_number] => 20200277380 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => PD-L1-SPECIFIC ANTIBODIES AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/818621 [patent_app_country] => US [patent_app_date] => 2020-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10470 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16818621 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/818621
PD-L1-specific antibodies and methods of using the same Mar 12, 2020 Issued
Array ( [id] => 16238294 [patent_doc_number] => 20200255528 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => B7-H4 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/814627 [patent_app_country] => US [patent_app_date] => 2020-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42768 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16814627 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/814627
B7-H4 antibodies and methods of use thereof Mar 9, 2020 Issued
Array ( [id] => 17867392 [patent_doc_number] => 20220290128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => CAR LIBRARY AND scFv MANUFACTURING METHOD [patent_app_type] => utility [patent_app_number] => 17/428214 [patent_app_country] => US [patent_app_date] => 2020-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 113216 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 276 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17428214 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/428214
CAR library and scFv manufacturing method Feb 3, 2020 Issued
Array ( [id] => 16468207 [patent_doc_number] => 20200369744 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => BSL2v2c2-Ig POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 16/778159 [patent_app_country] => US [patent_app_date] => 2020-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70101 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16778159 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/778159
BSL2v2c2-Ig POLYPEPTIDES Jan 30, 2020 Abandoned
Array ( [id] => 18717878 [patent_doc_number] => 11795209 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-24 [patent_title] => PVRIG polypeptides and methods of treatment [patent_app_type] => utility [patent_app_number] => 16/775133 [patent_app_country] => US [patent_app_date] => 2020-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 223 [patent_figures_cnt] => 345 [patent_no_of_words] => 58474 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16775133 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/775133
PVRIG polypeptides and methods of treatment Jan 27, 2020 Issued
Array ( [id] => 16807915 [patent_doc_number] => 20210130468 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => Antigen Binding Proteins that Bind PD-1 [patent_app_type] => utility [patent_app_number] => 16/742712 [patent_app_country] => US [patent_app_date] => 2020-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23922 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16742712 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/742712
Antigen binding proteins that bind PD-1 Jan 13, 2020 Issued
Array ( [id] => 15866303 [patent_doc_number] => 20200140555 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS [patent_app_type] => utility [patent_app_number] => 16/728642 [patent_app_country] => US [patent_app_date] => 2019-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34046 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 177 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16728642 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/728642
Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the CNS Dec 26, 2019 Issued
Array ( [id] => 18341911 [patent_doc_number] => 11639385 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-02 [patent_title] => Anti-PD-1 antibodies [patent_app_type] => utility [patent_app_number] => 16/728653 [patent_app_country] => US [patent_app_date] => 2019-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 37 [patent_no_of_words] => 18519 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16728653 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/728653
Anti-PD-1 antibodies Dec 26, 2019 Issued
Array ( [id] => 18355074 [patent_doc_number] => 11643464 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-09 [patent_title] => Reducing systemic regulatory T cell levels or activity for treatment of a retinal degeneration disorder [patent_app_type] => utility [patent_app_number] => 16/728587 [patent_app_country] => US [patent_app_date] => 2019-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 76 [patent_no_of_words] => 28533 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16728587 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/728587
Reducing systemic regulatory T cell levels or activity for treatment of a retinal degeneration disorder Dec 26, 2019 Issued
Array ( [id] => 19931740 [patent_doc_number] => 12304937 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-20 [patent_title] => Leptin immunogens, hybridoma cells, monoclonal antibodies, polyclonal antibodies and use thereof [patent_app_type] => utility [patent_app_number] => 17/424484 [patent_app_country] => US [patent_app_date] => 2019-12-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 808 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17424484 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/424484
Leptin immunogens, hybridoma cells, monoclonal antibodies, polyclonal antibodies and use thereof Dec 23, 2019 Issued
Array ( [id] => 18518531 [patent_doc_number] => 11708412 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-25 [patent_title] => Methods for treating hematologic cancers [patent_app_type] => utility [patent_app_number] => 16/724759 [patent_app_country] => US [patent_app_date] => 2019-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 23 [patent_no_of_words] => 40119 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16724759 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/724759
Methods for treating hematologic cancers Dec 22, 2019 Issued
Array ( [id] => 16900797 [patent_doc_number] => 20210179713 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => ANTI-PD-1 ANTIBODIES, ACTIVATABLE ANTI-PD-1 ANTIBODIES, AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/725587 [patent_app_country] => US [patent_app_date] => 2019-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 118076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16725587 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/725587
ANTI-PD-1 ANTIBODIES, ACTIVATABLE ANTI-PD-1 ANTIBODIES, AND METHODS OF USE THEREOF Dec 22, 2019 Abandoned
Array ( [id] => 16206552 [patent_doc_number] => 20200239542 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => B7-H5, A Costimulatory Polypeptide [patent_app_type] => utility [patent_app_number] => 16/707719 [patent_app_country] => US [patent_app_date] => 2019-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10850 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16707719 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/707719
B7-H5, a costimulatory polypeptide Dec 8, 2019 Issued
Array ( [id] => 15678403 [patent_doc_number] => 20200093865 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/701818 [patent_app_country] => US [patent_app_date] => 2019-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69312 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16701818 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/701818
Genetically engineered hematopoietic stem cells and uses thereof Dec 2, 2019 Issued
Array ( [id] => 18020607 [patent_doc_number] => 20220372106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => CD86 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/298506 [patent_app_country] => US [patent_app_date] => 2019-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79249 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -171 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17298506 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/298506
CD86 variant immunomodulatory proteins and uses thereof Nov 26, 2019 Issued
Array ( [id] => 16156605 [patent_doc_number] => 20200216535 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-09 [patent_title] => ANTI-PD1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS [patent_app_type] => utility [patent_app_number] => 16/684237 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16072 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16684237 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/684237
Anti-PD1 antibodies and their use as therapeutics and diagnostics Nov 13, 2019 Issued
Array ( [id] => 17312838 [patent_doc_number] => 20210401886 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => METHODS AND MATERIALS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/288212 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7611 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17288212 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/288212
Methods and materials for treating cancer Oct 30, 2019 Issued
Menu